Albumin-to-alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation-negative advanced non-small cell lung cancer

被引:6
作者
Liu, Xiaoqin [1 ]
Li, Yan [1 ]
Zhao, Qi [1 ]
Jiang, Hanyi [1 ]
Ni, Jun [2 ]
Cai, Hourong [1 ]
机构
[1] Nanjing Med Univ, Dept Pulm & Crit Care Med, Affiliated Nanjing Drum Tower Hosp, Clin Med Coll, Nanjing 210008, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Clin Lab Med, Affiliated Nanjing Drum Tower Hosp, Clin Med Coll, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
albumin‐ to‐ alkaline phosphatase ratio; driver mutation‐ negative advanced non‐ small cell lung cancers(DANSCLCs); prognosis; treatment choice;
D O I
10.1111/crj.13339
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction Albumin-to-Alkaline Phosphatase Ratio (AAPR), a novel developed prognostic index for cancers. Chemotherapy was the only method for driver mutation-negative advanced non-small cell lung cancer (DANSCLC). Objectives To evaluate the clinical significance of AAPR in these patients. Methods We retrospectively reviewed 167 DANSCLCs and 58 healthy controls. Associations of clinicopathological characteristics and survival analysis were conducted. Results Significantly decreased AAPR level was uncovered in DANSCLC patients compared to healthy controls. The correlation analysis revealed that the low AAPR level in DANSCLCs was correlated with poor differentiation (P = .024). Cox regression analysis showed that N stage, M stage, and different levels of AAPR were the independent risk factors of PFS and OS. The median PFS and OS survival ratio in patients with high and low AAPR level was, respectively, 17 months and 8 months, and 23 months and 13 months. The AUC of AAPR for both PFS and OS were higher than that of albumin and alkaline phosphatase (p < 0.05). The low AAPR was associated with much shorter PFS and OS than the high AAPR (mPFS: 8 vs. 25 months; mOS: 12 vs. 36 months). In the AP cohort, the low AAPR group experienced significantly shorter PFS and OS than the high AAPR (mPFS: 7 vs. 25 months; mOS: 12 vs. 36 months). Meanwhile, there was no significance in lung squamous cell carcinoma (LUSC) patients and GP regimens cohort. Conclusion AAPR significantly decreased in patients with DANSCLC, and it affects the prognosis of patients with DANSCLC and is a biomarker for DANSCLCs prognosis and treatment choice.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 30 条
[1]   Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies [J].
Cai, Xiurong ;
Chen, Zhanhong ;
Chen, Jie ;
Ma, Xiaokun ;
Bai, Mingjun ;
Wang, Tiantian ;
Chen, Xiangwei ;
Wu, Donghao ;
Wei, Li ;
Li, Xing ;
Lin, Qu ;
Wen, Jingyun ;
Ruan, Danyun ;
Lin, Zexiao ;
Dong, Min ;
Wu, Xiangyuan .
JOURNAL OF CANCER, 2018, 9 (01) :189-197
[2]  
Caravaca-Fontán F, 2017, NEFROLOGIA, V37, P267, DOI [10.1016/j.nefro.2016.11.010, 10.1016/j.nefroe.2017.04.015]
[3]   Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma [J].
Chan, Anthony W. H. ;
Chan, Stephen L. ;
Mo, Frankie K. F. ;
Wong, Grace L. H. ;
Wong, Vincent W. S. ;
Cheung, Yue-Sun ;
Chan, Henry L. Y. ;
Yeo, Winnie ;
Lai, Paul B. S. ;
To, Ka-Fai .
DISEASE MARKERS, 2015, 2015 :1-10
[4]   Cancer incidence and mortality in China, 2007 [J].
Chen, Wan-qing ;
Zeng, Hong-mei ;
Zheng, Rong-shou ;
Zhang, Si-wei ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) :1-8
[5]   A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel [J].
Chi, K. N. ;
Kheoh, T. ;
Ryan, C. J. ;
Molina, A. ;
Bellmunt, J. ;
Vogelzang, N. J. ;
Rathkopf, D. E. ;
Fizazi, K. ;
Kantoff, P. W. ;
Li, J. ;
Azad, A. A. ;
Eigl, B. J. ;
Heng, D. Y. C. ;
Joshua, A. M. ;
de Bono, J. S. ;
Scher, H. I. .
ANNALS OF ONCOLOGY, 2016, 27 (03) :454-460
[6]   SERUM-ALBUMIN AND OTHER PROGNOSTIC FACTORS RELATED TO RESPONSE AND SURVIVAL IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER [J].
ESPINOSA, E ;
FELIU, J ;
ZAMORA, P ;
BARON, MG ;
SANCHEZ, JJ ;
ORDONEZ, A ;
ESPINOSA, J .
LUNG CANCER, 1995, 12 (1-2) :67-76
[7]   The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[8]   Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review [J].
Jafri, Syed H. ;
Shi, Runhua ;
Mills, Glenn .
BMC CANCER, 2013, 13
[9]   Survival Analysis of Advanced Non-Small Cell Lung Cancer Patients Treated by Using Wheel Balance Cancer Therapy [J].
Kim, Jongmin ;
Cho, Chong-Kwan ;
Yoo, Hwa-Seung .
INTEGRATIVE CANCER THERAPIES, 2016, 15 (04) :467-477
[10]   Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer [J].
Kimura, Madoka ;
Naito, Tateaki ;
Kenmotsu, Hirotsugu ;
Taira, Tetsuhiko ;
Wakuda, Kazushige ;
Oyakawa, Takuya ;
Hisamatsu, Yasushi ;
Tokito, Takaaki ;
Imai, Hisao ;
Akamatsu, Hiroaki ;
Ono, Akira ;
Kaira, Kyoichi ;
Murakami, Haruyasu ;
Endo, Masahiro ;
Mori, Keita ;
Takahashi, Toshiaki ;
Yamamoto, Nobuyuki .
SUPPORTIVE CARE IN CANCER, 2015, 23 (06) :1699-1708